The UK and US have reached a significant bilateral deal that will preserve zero duties on British pharmaceutical products going into the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has committed to increase funding on pharmaceuticals through the public health system. This pledge guarantees that import taxes on these crucial exports will be held at nothing for a duration of 36 months.
This agreement comes after previous threats to significantly raise tariffs on patented pharmaceutical imports, with potential rates mentioned reaching 100%.
"This deal with the United Kingdom reinforces the global environment for innovative medicines and brings much-needed fairness to transatlantic drug exports," an announcement noted.
Economic Impact
Medicines represent one of the UK's biggest exports to the America, which is by far the largest destination for leading British pharmaceutical firms.
Statistics indicate that in the one-year period leading up to last September, the UK exported drugs totaling £11.1bn to the US. This figure made up 17.4% of British export trade in that period.
"This deal protects jobs, stimulates funding and sets the stage for the UK to become a international leader for life sciences," the Business and Trade Secretary remarked.
Detailed British Pledges
The agreement includes several notable changes from the UK:
- Price Threshold Increase: The UK will lift the affordability limit at which it deems new treatments to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a aim to increase overall NHS spending on medicines from 0.3% of the national economy to 0.6% over the following ten-year period.
- Payback Limit: The sum manufacturers must pay back to the NHS to stay within budget will be restricted at 15%. Previously, refunds topped twenty percent.
Recent Tensions
This agreement follows a long-running row between the drug companies and the UK government over medicine costs and NHS adoption.
These tensions were intensified by claims that American patients were charged significantly more for the equivalent treatments than people in the Britain and the EU.
In recent months, several significant drug company projects in the UK have been delayed or cancelled, while substantial expansions have been directed toward American operations.
A senior figure publicly accepted that the NHS needed to invest a greater share on drugs, noting that its expenditure on drugs had shrunk as a percentage of its total funding over the last ten years.
